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Abstract
Background: To evaluate the safety and efficacy of abiraterone acetate (AA) in the “real life” clinical practice for
men with chemotherapy-naïve metastatic castration-resistant prostate.
Methods: A consecutive series of patients with mCRPC in 9 Italian tertiary centres treated with AA was collected.
Demographics, clinical parameters, treatment outcomes and toxicity were recorded. The Brief Pain Inventory scale
Q3 was tracked and patient treatment satisfaction was evaluated. Survival curves were estimated by the method of
Kaplan-Meier and Cox regression and compared by the log-rank test statistic.
Results: We included 145 patients (mean age 76.5y). All patients were on androgen deprivation therapy. Patients
had prior radiotherapy, radical prostatectomy, both treatments or exclusive androgen deprivation therapy in 17%,
33%, 9% and 40%, respectively. 57% of the patients had a Gleason score higher more than 7 at diagnosis. 62%
were asymptomatic patients. The median serum total PSA at AA start was 17 ng/mL (range 0,4–2100). The median
exposure to AA was 10 months (range 1–35). The proportion of patients achieving a PSA decline ≥50% at 12 weeks
was 49%. Distribution of patient satisfaction was 32% “greatly improved”, 38% “improved”, 24% “not changed”, 5.5%
“worsened”. Grade 3 and 4 toxicity was recorded in 17/145 patients 11.7% (70% cardiovascular events, 30% critical
elevation of AST/ALT levels). At the last follow-up, median progression free and overall survival were 17 and 26.
5 months, respectively. Both outcomes significantly correlated with the presence of pain, patient satisfaction, PSA
baseline and PSA decline.
Conclusions: The AA is effective and well tolerated in asymptomatic or slightly symptomatic mCRPC in a “real life”
setting. The survival outcomes are influenced by the presence of pain, patient satisfaction, baseline PSA and PSA decline.
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Trial registration: The study was retrospectively registered at ISRCTN as DOI:10.1186/ISRCTN 52513758 in date April the
30th 2016.
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Background
Prostate cancer (PCa) is the most common male
neoplasm and the second leading cause of death from
cancer [1].
External beam radiation therapy and surgery are the
best options for the treatment of a localized disease,
however after an initial treatment with curative intent
almost 34% of patients developed progressive meta-
static disease [2]. Currently, about 5% of the men
were newly diagnosed with metastatic PCa, compared
with 20–25% >20 yr. ago [3].
For patients with progressive, recurrent and/or
metastatic PCa the androgen deprivation therapy
(ADT) is the main therapeutic option, even though
the progression to a castration-resistant state invari-
ably occurs after a median time of 18–24 months [3].
The median time from the diagnosis of metastatic
disease to death is about 40 months. The metastatic
castration-resistant prostate cancer (mCRPC) is the
final common pathway in the disease continuum of
PCa and remains a clinically relevant phenotype with
an elevated burden of mortality. Several mechanisms
have been proposed to explain the acquisition of the
castration-resistant prostate cancer status including
the upregulation of the androgen receptor (AR), in-
duction of AR splice variants, AR point mutations,
upregulation of glucocorticoid receptors, activation of
alternative oncogenic signaling pathways, neuroendo-
crine transformation and immune evasion via PD-L1
upregulation [4, 5].
Nowadays several treatments are available for the
management of mCRPC prior to chemotherapy. In par-
ticular, abiraterone acetate (AA) has been used in several
studies and in different clinical settings, demonstrating
the reliability and the robustness of the oncological re-
sults of AA in terms of overall survival, PSA progression,
radiological free survival, time to opiate, etc. [6–12].
Notwithstanding these RCTs, few studies have evaluated
the role of AA in managing chemonaive mCRPC in a
“real life” setting [12, 13].
The aim of our study was to evaluate the safety and
efficacy of AA plus the prednisone regimen in mCRPC




The study was registered at ISRCTN as DOI:10.1186/
ISRCTN 52513758. A consecutive series of 145 (November
2013–June 2016) patients with progressive mCRPC and
castrate levels of testosterone (<50 ng/dl), chemonaive,
treated with AA plus prednisone in 9 Italian tertiary
cancer centers were enrolled in a dedicated database
(Additional file 1). Patients with visceral metastases were
included only if they were not fit for chemotherapy. Four
patients, in one center, received AA plus prednisone for
compassionate use before the final version of the COU-
AA 302 study.
Patients were treated with AA 1000 mg once daily in
association with prednisone 5 mg twice a day until
progression, death or unacceptable toxicity.
A physical examination, laboratory studies (including a
full blood count, routine biochemistry and serum PSA),
were carried out at baseline and at visits every 4 weeks.
Patients were reviewed every 4 wk. until disease progres-
sion occurred or treatment was discontinued for other
reasons. Periodic re-evaluation with imaging was per-
formed every 12–16 weeks as required by the Italian
Medicine Agency (Agenzia Italiana Farmaco, AIFA) for
the AA prescription.
Demographics, clinical parameters, treatment out-
comes and toxicity events were recorded. The Gleason
score at the diagnosis was recorded. The performance
status was measured by the Eastern Cooperative Oncol-
ogy Group (ECOG) and the pain by the Brief Pain In-
ventory scale [9]. At the 6 month follow-up visit patients
were asked to rate the extent to which they were
subjectively improved with the AA treatment on a 4-
point, arbitrary, not validated scale. The categories were:
1- greatly improved, 2- improved, 3- not changed, 4-
worsened.
Treatment-related toxicity was collected and graded
monthly according to the National Cancer Institute
Common Terminology Criteria for Adverse Events 4.02
toxicity scale.
Overall Survival (OS) was defined as the time between
treatment initiation and either the date of death or of
the last follow-up for surviving patients. Progression free
survival (PFS) was defined as the time from the first
Cindolo et al. BMC Cancer  (2017) 17:753 Page 2 of 8
dose of AA to the first clinical (pain, general status) or
new radiographic event.
The PSA decline was defined as a response at 12 weeks
equal or greater than 50% in the PSA relative to the
baseline.
Statistical analysis
Data were analyzed using SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA) and R software version 3.1.0 (R
Foundation for Statistical Computing, Vienna, Austria).
Continuous variables were reported as either mean and
standard deviation (SD) or median and range on the
basis of their distribution. Comparisons of variables
among groups were performed by the one-way ANOVA
or Kruskal–Wallis test. Categorical variables were
expressed as the absolute number and percentage and
analyzed by the Chi-square test. Survival curves were es-
timated by the product-limit method of Kaplan-Meier
and compared using the log-rank statistics. The Cox re-
gression model was used to estimate the hazard ratio
(HR) and 95% confidence intervals (CI). An alpha value
of 5% was considered as the threshold for significance.
Results
Overall, 145 patients who initiated AA between November
2013 and June 2016 were enrolled. Table 1 summarizes
the characteristics of the patient cohort. In particular, the
median age was 76.5 years and 33.8% had already received
surgery, whereas 40% of the patients were treated with
ADT only. Patients with a Gleason score higher than 7 at
diagnosis represented 57.5% of the series. About 38% of
patients were symptomatic prior to the initiation of AA,
with an ECOG-PS ranging between 0 and 1 in 93% of sub-
jects. Only 11% of patients received more than 2 hormo-
nal manipulations before AA.
The ADT lasted more than 12 months in 77.9% of pa-
tients, with a median time of mCRPC development of
5 years. The median serum total PSA at baseline was
17.4 ng/mL (range 0.4–2100). Overall the median
Table 1 Patient characteristics (n = 145)
Variable Value
Age years, mean (sd) 76.5 (7.0)
ECOG performance status, No. (%) (missing = 14)
0–1 125 (95)
> 2 6 (5)
Presence of Pain, yes, n (%) 56 (38.6)
Brief Pain Inventory Question #3, >2,
n (%), (missing =13)
46 (34.9)
Baseline PSA, median (range) 17.4 (0.4 to 2100.0)
Baseline ALT, median (range) 20 (8–87)
Baseline AST, median (range) 18.5 (6–309)
Gleason at time of initial diagnosis,
n (%) (missing = 4)
> 7 81 (57.5)
Local treatment, n (%)
None 58 (40.0)
External Beam Radiation Therapy 25 (17.2)
Radical Prostatectomy 49 (33.8)
Both 13 (8.9)
Disease location, n (%) (missing =5)
Bone only 75 (53.5)
Lymph nodes only 22 (15.7)
Visceral only 4 (2.8)
Prostatic fossa only 11 (7.8)
Multiple sites 28 (20.0)
Comorbidity, n (%)
None 33 (22.7)
Cardiovascular only 50 (35.7)
Metabolic only 8 (5.5)
Multiple (cardiovascular + metabolic) 26 (17.9)
Other 28 (19.3)
Time to mCRPC from initial diagnosis years,
median (range)
5.0 (0.2 to 17.7)
Hormonal manipulations before AA >2, n (%) 22 (15.2)
Duration of ADT >12 m, n (%) 113 (77.9)
Abreviations: mCRPC metastatic castration resistant prostate cancer,
ECOG Eastern Cooperative Oncology Group, PSA prostate specific antigen,
AA abiraterone acetate, ALT alanine aminotransferase, AST aspartate
aminotransferase, ADT androgen deprivation therapy
Table 2 Treatment details
Variable Value
N of cycles of AA, median (range) 10 (1–35)
Last PSA, median (range), n = 130 9.7 (0.0 to 2743.0)
12 weeks PSA, median (range), n = 99 7.7 (0.0 to 900.0)
12 weeks PSA decline, n (%), n = 99 49 (49.5)
12 weeks ALT, median (range), n = 58 22 (88–215)
12 weeks AST, median (range), n = 58 23 (9–150)
Patients’ subjective impression on AA regimen, n = 108 (missing =27)
1 = greatly improved 35 (32.4)
2 = improved 41 (37.9)
3 = not changed 26 (24.0)
4 = worsened 6 (5.5)
Median follow-up time, month (IQR) 13.6 (7–16)
Death, n (%) 33 (22.8)
Progression, n (%) 56 (38.6)
Median PFS, month (95% CI) 18.5 (16–20)
Median OS, month (95% CI) 26.5 (21–32)
Abreviations: PSA prostate specific antigen, AA abiraterone acetate, ALT alanine
aminotransferase, AST aspartate aminotransferase, PFS progression free survival,
OS overall survival
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exposure to AA was 10mo (range 1–35) (1 cycle =
1 month), with a 51% rate of dropout (66% for disease
progression/clinical deterioration, 14.8% for death, 10.8%
lost to follow-up, 8.1% for toxicity) (Table 2). Specifically,
relevant toxicity (Grade 3 and 4) was recorded in 17 out
of 145 patients (11.7%): 12 had cardiovascular events, 5
had a critical elevation of AST/ALT levels (within the 4th
month).
At the last follow up 50.3% of the patients were still
on active treatment with a median PSA of 9,7 ng/mL.
Fig. 1 Waterfall plot showing the 12w PSA decline in patients with follow-up >3 months (%). A negative percentage indicates a decline in PSA.
A positive percentage indicates that the patient never had a decline in PSA
Fig. 2 PFS according to different clinical variables: a) Pain (solid line = no; dotted line = yes); b) patient satisfaction in patients with follow-up
>3 months (solid line = satisfied + very satisfied; dotted line = worsened + not modified); b) baseline PSA (solid line = <17 ng/ml; dotted line
=≥17 ng/ml); d) 12w PSA decline in patients with follow-up >3 months (solid line = <50%; dotted line ≥50%)
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Among patients treated for more than 3 months 53.2%
achieved a PSA decline ≥50% (Fig. 1).
The patient subjective impression regarding the AA
regimen was recorded at a 6 month follow-up visit on
108 patients (27 patients missing) and was described as
“greatly improved”, “improved”, “not changed”, “wors-
ened” (32.4%, 37.9%, 24% and 5.5%, respectively)
(Table 2). Ten patients abandoned the AA regimen be-
fore reaching the 6 month check point.
The estimated median PFS was 18 months (95% CI 16–
20 months). The PFS was significantly associated with pa-
tient satisfaction (p < 0.001) [HR 3.37 (95% CI 1.75–6.50)],
pain (p < 0.001) [HR 3.28 (95% CI 1.92–5.61)], baseline
PSA (p = 0.018) [HR 1.94 (95% CI 1.12–3.34)] and PSA
decline (p = 0.029) [HR 0.44 (95% CI 0.21–0.92)] (Fig. 2).
The estimated overall survival was 26.5 months
(95% CI 21–32 months). Overall survival was associ-
ated with satisfaction (p = 0.02) [HR 3.16 (95% CI
1.20–8.32)], pain (p < 0.001) [HR 4.40 (95% CI 2.12–
9.12)] and PSA decline (p = 0.046) [HR 0.26 (95% CI
0.07–0.98)] (Fig. 3).
Discussion
In the current study, we have depicted a representative
snapshot regarding the efficacy of AA in an unselected
patient population as in a “real life” scenario. Herein,
with a mid term follow-up, we confirmed that AA plus
prednisone is an effective treatment with excellent pa-
tient satisfaction (“greatly improved/improved”: 69.2%)
and with a good safety profile (Grade 3 and 4 toxicity re-
corded in 11.7%). However, in a different setting (real life
vs RCT) of different mCRPC patients (older patients,
with lower value of baseline PSA, and shorter follow-up)
we obtained results in terms of survival outcomes com-
parable with those reported in the COU-302 trial [6]. In
particular, we observed a median OS of 26.5 (95% CI
21–32) versus 34.7 (95% CI 32–36) months in our study.
Moreover, our patients received a median of 10 AA cy-
cles (instead of 13.8 in the COU-302 trial) and were
followed for 13.6 months (instead of 49.2 in the COU-
302 trial), nevertheless the drug related adverse events
leading to treatment discontinuation was almost the
same (8.1% vs 7%) [6].
Although our trial was not designed to compare the
effect of AA vs placebo as in the COU302 trial and com-
parison with this study is extremely difficult, our experi-
ence confirms that AA, in a real life setting, could be
safely used to manage patients with chemonaive mCRPC
and obtain good results regarding cancer control and
patient satisfaction. The phenomenon of variations in
Fig. 3 OS according to different clinical variables: a) Pain (solid line = no; dotted line = yes); b) patient satisfaction in patients with follow-up
>3 months (solid line = satisfied + very satisfied; dotted line = worsened + not modified); c) baseline PSA (solid line = <17 ng/ml; dotted line
=≥17 ng/ml); d) 12w PSA decline in patients with follow-up >3 months (solid line = <50%; dotted line ≥50%)
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terms of efficacy-effectiveness between RCT and real life
studies clearly is not specific for AA treatment. In the
mCRPC field, similar results have also been reported on
the clinical effect of docetaxel in 2013 [14].
In modern oncology a wider space has been recog-
nized as the so-called “Patient Reported Outcomes”
(PROs), to warrant that the overall efficacy and safety
profiles of new therapies reflect patient experience and
perceptions [15, 16]. We think that the patient satisfac-
tion rating scale used in our study, which may be
considered a proxy of other and more complex PROs,
has given us a new insight into the AA therapy even
with its extreme simplicity. Albeit a missing not negli-
gible data rate (27/108), for the first time we analyzed
and published the patients’ subjective impression on the
AA regimen as a potential predictor of the survival
variables documenting a good correlation with both PFS
and OS (Figs. 1 and 2) [17, 18].
We also confirmed, as observed in the posthoc
analysis of the COU 302 trial [19], that patients with a
higher PSA level at baseline and suffering from signifi-
cant pain at baseline are at a higher risk for an unsatis-
factory outcome under AA treatment. Again, herein,
even in a real life setting, we demonstrated that some
patient characteristics (PSA and pain) better reflect a
better response to the treatment; further studies and
models are needed to exactly identify which patients
mostly benefit from the AA treatment.
Real life data on AA in mCRPC are available in Asian
and Danish populations [12, 13]. Unfortunately, our ex-
perience is not comparable with the data presented by
Poon, considering that they enrolled patients with more
advanced and aggressive disease (40% visceral metastatic
disease vs 2.8%; and median baseline PSA 212 versus
17 ng/ml). Furthermore, in the Asian study the patients
were not followed using a standard protocol and toxicity
was retrospectively evaluated without a centralized con-
trol, which on the contrary is mandatory in Italy. These
different baseline characteristics could explain the main
differences observed in terms of dropout rates (39% vs
51%), toxicity requiring AA discontinuation (5.2 vs
11.2%), disease progression rates (64% vs 38.6%) and
median PFS (6.7 vs 18.5 months). On the other hand,
even the comparison with the Danish population seems
to be difficult. We enrolled and treated an older popula-
tion (76 vs 71 years) with a probably less aggressive dis-
ease (baseline PSA 17 vs 156 ng/ml). With a prolonged
exposure to the AA (10 vs 5.3 cycles) we recorded a not
negligible improvement in overall survival (25 vs
16.6 months) obtaining a better PSA decline control
(50% vs 36%). Taken together, these observations suggest
that even in a real life setting AA treatment in patients
with a less aggressive and less advanced disease in terms
of PSA and visceral/nodal metastases is associated with
a better outcome, as also highlighted in 2016 by Miller
[19] and recently showed by Bögemann [20] during the
last ASCO meeting.
We must acknowledge some important limitations to
our study. It is a retrospective analysis of a prospective
collected database and it includes all the possible limita-
tions of these studies such as the under-reporting of ad-
verse events, incompleteness of data collection and
selection biases. However, all these possible drawbacks
did not affect the ability to correctly evaluate the sur-
vival outcomes, especially due to the peculiar dispensing
procedures for AA in Italy. Specifically, the prescription
and the dispensation of AA in our country are monthly
checked and confirmed in case of clinical benefit with-
out critical toxicity. All these data are collected by physi-
cians and ensure a meticulous observation and report of
progressive disease and/or fatal events. The length of the
follow-up is another limit of the study and a future re-
port is necessary. Also, the use of a non validated tool to
evaluate patient satisfaction regarding treatment should
be considered a limitation. When we started our study
AA was the only approved drug for mCRPC patients
considering that enzalutamide treatment has been avail-
able since February 2016. So far we have no real life data
on the new available treatment modalities used to man-
age mCRPC. However, to the best of our knowledge, no
studies are available in the literature evaluating enzaluta-
mide, or radium-223 in a real life setting.
Notwithstanding all these limitations, our study repre-
sents an early multicentre European real life experience
evaluating the effect of AA in mCRPC, and shows that,
even in this different clinical scenario, it is associated
with a significant effect on oncological and PRO out-
comes similar to what has been observed in RCTs, even
if further subsequent evaluations were warranted.
Conclusion
Our data confirm that in a “real life” setting (in a popu-
lation different in terms of age and comorbidities
compared with RCT), AA treatment is effective and safe
in mCRPc naïve chemotherapy patients. The survival
outcomes are influenced by the presence of pain, patient
satisfaction, baseline PSA and PSA decline. A prolonged
follow-up is needed to definitely evaluate long term sur-
vival outcomes.
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